These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18288564)
1. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Vehreschild JJ; Böhme A; Reichert D; Kiehl MG; Arenz D; Pankraz K; Kochanek M; Ullmann AJ; Cornely OA Int J Hematol; 2008 Mar; 87(2):126-131. PubMed ID: 18288564 [TBL] [Abstract][Full Text] [Related]
2. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089 [TBL] [Abstract][Full Text] [Related]
3. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233 [TBL] [Abstract][Full Text] [Related]
4. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607 [TBL] [Abstract][Full Text] [Related]
5. [Current indications for voriconazole in onco-hematological patients]. Jarque I; Sanz MA Rev Iberoam Micol; 2007 Sep; 24(3):213-6. PubMed ID: 17874858 [TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564 [TBL] [Abstract][Full Text] [Related]
7. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283 [TBL] [Abstract][Full Text] [Related]
8. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090 [TBL] [Abstract][Full Text] [Related]
9. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? Cherif H; Kalin M; Björkholm M Eur J Haematol; 2006 Oct; 77(4):288-92. PubMed ID: 16856930 [TBL] [Abstract][Full Text] [Related]
10. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Przepiorka D; Buadi FK; McClune B Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475 [TBL] [Abstract][Full Text] [Related]
11. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. Heinz WJ; Silling G; Böhme A Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707 [TBL] [Abstract][Full Text] [Related]
12. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251 [TBL] [Abstract][Full Text] [Related]